PRESS RELEASE published on 07/25/2025 at 08:00, 10 months 28 days ago Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) Abivax announces full exercise of underwriters’ option to purchase additional ADSs, bringing gross proceeds of offering to $747.5M (€637.5M). Company to apply net proceeds to identified use of funds Abivax Underwriters ADSs Offering Proceeds
BRIEF published on 07/24/2025 at 14:45, 10 months 29 days ago Abivax's $650M Public Offering of ADS Biotechnology Abivax Capital Increase Public Offering Ads
BRIEF published on 07/24/2025 at 14:45, 10 months 29 days ago Abivax lance une offre publique d'ADS de 650 millions de dollars Biotechnologie Abivax Augmentation De Capital Offre Publique PUBLICITÉS
PRESS RELEASE published on 07/24/2025 at 14:40, 10 months 29 days ago Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements thérapeutiques pour les maladies inflammatoires chroniques Euronext Paris Biotechnologie Abivax Traitements Thérapeutiques Maladies Inflammatoires
PRESS RELEASE published on 07/24/2025 at 14:40, 10 months 29 days ago Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares pour financer le développement de thérapies biotechnologiques. Details de l'offre, stabilisation et prévisions financières Biotechnologie Abivax Ads Offre Publique Modalités Définitives
PRESS RELEASE published on 07/24/2025 at 14:40, 10 months 29 days ago Abivax announces trading resumption of its ordinary shares on Euronext Paris Abivax announces the trading resumption of its ordinary shares on Euronext Paris after a temporary halt for a public offering confirmation and pricing announcement Euronext Paris Abivax Public Offering Clinical-stage Biotechnology Trading Resumption
PRESS RELEASE published on 07/24/2025 at 14:40, 10 months 29 days ago Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements pour les maladies inflammatoires chroniques Euronext Paris Biotechnologie Abivax Négociations Traitements
PRESS RELEASE published on 07/24/2025 at 14:40, 10 months 29 days ago Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares Abivax announces pricing of $650M (€554M) public offering of American Depositary Shares to fund clinical development and working capital, with expected closing on July 28, 2025 Abivax Clinical Development Public Offering Pricing Closing
PRESS RELEASE published on 07/24/2025 at 14:40, 10 months 29 days ago Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares Abivax annonce les modalités de son offre de 650M$ d'American Depositary Shares pour financer des développements cliniques. Stabilisation et options incluses Abivax Développement Clinique Offre Publique Stabilisation American Depositary Shares
BRIEF published on 07/24/2025 at 07:35, 10 months 29 days ago Abivax suspend temporairement sa cotation sur Euronext Paris Euronext Paris Biotechnologie Abivax Offre Publique Suspension Des Échanges
Published on 06/22/2026 at 23:05, 6 minutes ago Gamma Resources Settles Remaining Balance of Outstanding Debt
Published on 06/22/2026 at 21:05, 2 hours 6 minutes ago RUM Announces Voting Results From Annual General Meeting of Shareholders
Published on 06/22/2026 at 19:45, 3 hours 26 minutes ago Trans Canada Gold Appoints Paradigm Drilling Ltd. for Drilling at the Harrison Lake District Scale Gold Project, Drilling to Commence Shortly
Published on 06/22/2026 at 15:58, 7 hours 13 minutes ago Metallic Minerals Closes Upsized C$10.3 Million Bought Deal LIFE Private Placement
Published on 06/22/2026 at 15:30, 7 hours 41 minutes ago NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
Published on 06/22/2026 at 21:07, 2 hours 4 minutes ago EQS-Adhoc: RWE Aktiengesellschaft: RWE sets placement price for shares from capital measure and raises gross proceeds of 4 billion EUR
Published on 06/22/2026 at 20:50, 2 hours 21 minutes ago Ethlabs, Founded by Former Ethereum Foundation Contributors and Funded by Bitmine, Sharplink and Joe Lubin, Launches to Accelerate Ethereum's Institutional Supercycle
Published on 06/22/2026 at 20:32, 2 hours 38 minutes ago EQS-Adhoc: Deutsche Konsum Real Estate AG: Daniel Löhken appointed Chief Executive Officer of the Company and Dr Kai Gregor Klinger appointed new Chairman of the Supervisory Board
Published on 06/22/2026 at 19:27, 3 hours 44 minutes ago Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Published on 06/22/2026 at 18:54, 4 hours 16 minutes ago EQS-Adhoc: Brenntag SE publishes preliminary operating EBITDA for the second quarter of 2026 and increases its guidance for the financial year 2026
Published on 06/22/2026 at 18:00, 5 hours 11 minutes ago GUILLEMOT CORPORATION : DECES DE M. CLAUDE GUILLEMOT, Président du Groupe GUILLEMOT CORPORATION